

CITATION REPORT

List of articles citing

**Cytokine network in congestive heart failure
secondary to ischemic or idiopathic dilated cardiomyopathy**

**DOI: 10.1016/s0002-9149(98)00872-8
American Journal of Cardiology, 1999, 83, 376-82.**

Source: <https://exaly.com/paper-pdf/30565948/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
401	New developments in IL-6 dependent biology and therapy: where do we stand and what are the options?. 1999 , 8, 1327-49		12
400	Is apoptosis an important pathogenic factor in cardiovascular disease?. 1999 , 29, 369-71		4
399	Mitochondrial Function in Heart Failure. 1999 , 4, 229-244		6
398	Possible role of proinflammatory cytokines in heart allograft coronary artery disease. <i>American Journal of Cardiology</i> , 1999 , 84, 999-1003	3	43
397	Elevated serum and monocyte tumour necrosis factor alpha in patients with congestive heart failure. 1999 , 71, 263-4		3
396	Levels of serum interleukin-10 reflect disease activity in patients with cardiac sarcoidosis. 2000 , 64, 755-9		16
395	Update on recent clinical trials in congestive heart failure. 2000 , 15, 293-303		11
394	Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction. 2000 , 215, 145-52		68
393	Insights into pathogenesis and treatment of cytokines in cardiomyopathy. 2000 , 2, 120-8		10
392	Leukemia Inhibitory Factor and Interleukin-6 downregulate sarcoplasmic reticulum Ca ²⁺ ATPase (SERCA2) in cardiac myocytes. 2000 , 95, 47-54		53
391	Biocompatibility of New Peritoneal Dialysis Solutions: What Can We Hope to Achieve?. 2000 , 20, 57-67		30
390	Procalcitonin: THE marker of sepsis?. 2000 , 28, 1226-8		52
389	Polymorphisms of tumor necrosis factor-alpha and interleukin-10 genes in Japanese patients with idiopathic dilated cardiomyopathy. 2000 , 41, 183-91		28
388	New therapies for heart failure: is thalidomide the answer?. 2000 , 93, 305-11		24
387	Circulating soluble gp130, soluble IL-6R, and IL-6 in patients undergoing cardiac surgery, with or without extracorporeal circulation. 2000 , 18, 98-103		36
386	Zytokine und Myokardfunktion. 2000 , 35, 782-784		
385	Plasma cytokine parameters and mortality in patients with chronic heart failure. 2000 , 102, 3060-7		634

384	gp130-Dependent signalling pathway is not enhanced in gp130 transgenic heart after LIF stimulation. 2000 , 12, 1512-8	17
383	The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. 2000 , 72, 175-86	140
382	Inflammatory mediators in heart failure. 2000 , 72, 209-13	31
381	Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. 2000 , 140, E28	47
380	Plasma interleukin-4, interleukin-10, and interleukin-13 concentrations and complications after coronary artery bypass graft surgery. 2000 , 14, 156-60	26
379	Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. 2001 , 37, 412-7	190
378	Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure--modulatory effect of intravenous immunoglobulin. 2001 , 38, 187-93	82
377	Pathophysiological role of cytokines in congestive heart failure. 2001 , 52, 15-27	116
376	TGF-beta1 gene polymorphisms in patients with end-stage heart failure. 2001 , 20, 979-84	45
375	Are macrophages involved in early myocardial reperfusion injury?. 2001 , 71, 1596-602	30
374	Myocardial tumor necrosis factor-alpha expression does not correlate with clinical indices of heart failure in patients on left ventricular assist device support. 2001 , 72, 2044-50	23
373	Managing heart failure with immunomodulatory agents. 2001 , 19, 617-25	7
372	[New pharmacological agents in heart failure]. 2001 , 54, 624-34	1
371	Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. 2001 , 104, 1494-500	59
370	Increase in Anti-Inflammatory Cytokine Levels in Chronic Heart Failure: A Measure of Treatment Success or Failure?. 2001 , 104,	
369	New strategies for the management of acute decompensated heart failure. 2001 , 16, 164-73	5
368	Activation of the cardiac interleukin-6 system in advanced heart failure. 2001 , 3, 415-21	56
367	[Tumor necrosis factor alpha in chronic heart failure. Clinical manifestation and therapeutic possibilities]. 2001 , 26, 437-46	2

366	Cytokines as new treatment targets in chronic heart failure. 2001 , 2, 271-277		34
365	Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. 2001 , 31, 389-97		66
364	Cytokines and their receptors in cardiovascular diseases--role of gp130 signalling pathway in cardiac myocyte growth and maintenance. 2000 , 81, 1-16		41
363	The role of interleukin-6 in the failing heart. 2001 , 6, 95-103		138
362	Effect of aerobic exercise training on plasma levels of tumor necrosis factor alpha in patients with heart failure. <i>American Journal of Cardiology</i> , 2001 , 88, 805-8	3	84
361	The time course of tumor necrosis factor-alpha, inducible nitric oxide synthase and vascular endothelial growth factor expression in an experimental model of chronic myocardial infarction in rats. 2001 , 38, 288-300		53
360	Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women@ health and aging study. 2001 , 103, 947-53		361
359	Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. 2001 , 103, 220-5		263
358	Hematopoiesis/erythropoiesis in myocardial infarcts. 2001 , 14, 589-94		13
357	Health effects and time course of particulate matter on the cardiopulmonary system in rats with lung inflammation. 2002 , 65, 1571-95		109
356	Inflammatory mediators and the failing heart: past, present, and the foreseeable future. 2002 , 91, 988-98		758
355	Imbalance of catabolic and anabolic pathways in chronic heart failure. 2002 , 46, 3-10		8
354	A case of peripartum cardiomyopathy with a transient increase of plasma interleukin-6 concentration occurred following mirror syndrome. 2002 , 30, 426-8		3
353	Who are the enemies? Inflammation and autoimmune mechanisms. 2002 , 4, G27-G32		6
352	Effect of thalidomide in patients with chronic heart failure. 2002 , 144, 847-50		42
351	Mechanisms of cytokine induced NO-mediated cardiac fibroblast apoptosis. 2002 , 283, H1958-67		33
350	Plasma concentrations of tumor necrosis factor-alpha in cats with congestive heart failure. 2002 , 63, 640-2		16
349	Polymorphisms in cytokine genes do not predict progression to end-stage heart failure in children. 2002 , 12, 461-4		3

348	Secretion of IL-6, IL-11 and LIF by human cardiomyocytes in primary culture. 2002 , 18, 199-205		74
347	Cytokines and anti-cytokine therapeutic approaches to chronic heart failure. 2002 , 13, 356		5
346	Cytokines, apoptosis and cachexia: the potential for TNF antagonism. 2002 , 85, 161-71		121
345	Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 2002 , 89, 996-9	3	27
344	Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 2002 , 90, 1118-22	3	69
343	The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. 2002 , 1592, 323-43		153
342	Immune and neurohormonal pathways in chronic heart failure. 2002 , 8, 23-8, 48		23
341	Dilated cardiomyopathies as a cause of congestive heart failure. 2002 , 27, 113-34		21
340	The enhanced plasma levels of soluble tumor necrosis factor receptors (sTNF-R1; sTNF-R2) and interleukin-10 (IL-10) in patients suffering from chronic heart failure are reversed in patients treated with beta-adrenoceptor antagonist. 2002 , 22, 83-92		14
339	Gene expression of colony-stimulating factors and stem cell factor after myocardial infarction in the mouse. 2002 , 175, 173-81		29
338	Chronic heart failure and the immune system. 2002 , 23, 325-40		16
337	Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases. 2003 , 252, 25-32		24
336	Immunomodulating therapy: new treatment modality in congestive heart failure. 2003 , 9, 64-9		11
335	Cardiopulmonary alterations in mRNA expression for interleukin-1beta, the interleukin-6 superfamily and CXC-chemokines during development of postischaemic heart failure in the rat. 2003 , 23, 263-8		9
334	Immunomodulating effects of 3-thia fatty acids in activated peripheral blood mononuclear cells. 2003 , 33, 426-33		16
333	Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. 2003 , 33, 941-8		64
332	C-reactive protein in acute myocardial infarction: association with heart failure. 2003 , 145, 1094-101		96
331	Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. 2003 , 108, 2317-22		742

- 330 Complexity of transcriptional regulation of the tumor necrosis factor-alpha gene. **2003**, 35, 1179-81
- 329 Interleukin-6 and tumor necrosis factor-alpha levels increase in response to maximal exercise in patients with chronic heart failure. **2003**, 87, 83-90 32
- 328 Immunosuppressive therapy for heart failure: a guide to patient selection. **2003**, 3, 321-4 1
- 327 Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. **2003**, 107, 1486-91 562
- 326 Atrial natriuretic peptide polarizes human dendritic cells toward a Th2-promoting phenotype through its receptor guanylyl cyclase-coupled receptor A. **2003**, 170, 5869-75 42
- 325 Distant effects of experimental renal ischemia/reperfusion injury. **2003**, 14, 1549-58 354
- 324 Role of soluble gp130 in the tumour necrosis factor-alpha expression and its production by peripheral blood mononuclear cells. **2003**, 12, 355-9
- 323 Leukemia inhibitory factor is augmented in the heart in experimental heart failure. **2003**, 5, 137-45 12
- 322 Inflammatory mediators and the failing heart: a translational approach. **2003**, 3, 161-82 82
- 321 Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. **2003**, 24, 2186-96 62
- 320 Changes in the cytokine network and complement parameters during open heart surgery. **2003**, 2, 19-24 15
- 319 Mediators in HIV-associated cardiovascular disease: a focus on cytokines and genes. **2003**, 17 Suppl 1, S29-35 13
- 318 Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. **2003**, 14, 515-21 55
- 317 Enhanced TNF alpha and oxidative stress in patients with heart failure: effect of TNF alpha on platelet O₂- production. **2003**, 90, 317-25 53
- 316 Serum but not myocardial TNF-alpha concentration is increased in pacing-induced heart failure in rabbits. **2003**, 285, R463-9 31
- 315 Reconstru fisiolgica do ventrculo esquerdo: o conceito de mxima redu ventricular e mxima resposta inflamatria. **2004**, 19, 353 1
- 314 Can sedentary patients with heart failure achieve the beneficial effect of exercise training without moving?. **2004**, 25, 104-6 7
- 313 TNF and congestive heart failure: therapeutic possibilities. **2004**, 8, 203-9 15

312	Exercise training for older chronic heart failure patients. 2004 , 14, 55-61		1
311	The pro- and anti-inflammatory markers in patients with acute myocardial infarction and chronic stable angina. 2004 , 14, 317		6
310	Anti-cytokine therapy in chronic heart failure: new approaches and unmet promises. 2004 , 6, F16-F21		5
309	Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). 2004 , 109, 1594-602		856
308	Impairment of HERG K(+) channel function by tumor necrosis factor-alpha: role of reactive oxygen species as a mediator. 2004 , 279, 13289-92		105
307	Soluble TNF-alpha and interleukin-6 receptors in the urine of heart failure patients. Their clinical value and relationship with plasma levels. 2004 , 6, 877-82		11
306	Increased expression of tumor necrosis factor-alpha converting enzyme and tumor necrosis factor-alpha in peripheral blood mononuclear cells in patients with advanced congestive heart failure. 2004 , 6, 869-75		24
305	Anti-inflammatory nature of exercise. 2004 , 20, 323-6		87
304	Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin. 2004 , 3, 221-7		34
303	Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. <i>American Journal of Cardiology</i> , 2004 , 94, 1326-8	3	94
302	The effect of medical treatment on the level of C-Reactive protein and leukocyte count in patients with congestive heart failure. 2004 , 13, 168-172		
301	TNFalpha in patients with congestive heart failure. 2004 , 99, 12-7		6
300	Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. 2004 , 19, 237-41		66
299	Is too much neurohormonal blockade harmful?. 2004 , 6, 169-75		4
298	Leukaemia inhibitory factor alters expression of genes involved in rat cardiomyocyte energy metabolism. 2004 , 180, 133-42		27
297	Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?. 2004 , 50, 1040-50		81
296	Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. 2004 , 109, 750-5		97
295	Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with dilated cardiomyopathy is not due to neutralization of anti-receptor autoantibody. 2004 , 37, 489-93		13

294	Therapeutic potential of anticytokine therapy in congestive heart failure. 2004 , 4, 169-77		9
293	Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. 2004 , 44, 1292-7		54
292	Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. 2004 , 94, 301-5		63
291	Association between the TNF-2 allele and a better survival in cardiogenic shock. 2004 , 125, 2232-7		10
290	Cytokine response to pulmonary thromboendarterectomy. 2004 , 126, 135-41		56
289	Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease. 2004 , 22, 583-92		23
288	Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure. 2005 , 106, 1992-4		75
287	Decreased serum lipoprotein levels as a guide for clinical severity in patients with idiopathic dilated cardiomyopathy. 2005 , 206, 219-24		4
286	Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women. 2005 , 53, 747-54		179
285	Candidate-based proteomics in the search for biomarkers of cardiovascular disease. 2005 , 563, 23-60		298
284	Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. 2005 , 20, 93-101		70
283	Targeted anticytokine therapy and the failing heart. <i>American Journal of Cardiology</i> , 2005 , 95, 9C-16C; discussion 38C-40C	3	76
282	Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. <i>American Journal of Cardiology</i> , 2005 , 95, 17C-23C; discussion 38C-40C	3	93
281	Interferon-gamma and interferon-beta affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosis. 2005 , 162, 112-21		48
280	Role of interleukin-6 in cardiomyocyte/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation. 2005 , 204, 428-36		94
279	Inhibition of progenitor dendritic cell maturation by plasma from patients with peripartum cardiomyopathy: role in pregnancy-associated heart disease. 2005 , 12, 265-73		17
278	Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. 2005 , 91, 32-7		51
277	End stage ischaemic heart failure. 2005 , 91, 37		

276	Immunosuppressive therapy for heart failure. 2005 , 1, 449-56	1
275	Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. 2005 , 37, 74-85	126
274	Agents targeting inflammation in heart failure. 2005 , 14, 557-66	31
273	Time-course of changes in the levels of interleukin 6 in acutely decompensated heart failure. 2005 , 100, 415-20	36
272	Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. 2005 , 103, 182-6	45
271	Fluorescence imaging microscopy of cellular markers in ischemic vs non-ischemic cardiomyopathy after left ventricular unloading. 2005 , 24, 454-61	5
270	Intracellular monocyte cytokine production and CD 14 expression are up-regulated in severe vs mild chronic heart failure. 2005 , 24, 854-9	26
269	Comparison of soluble glycoprotein 130 and cardiac natriuretic peptides as long-term predictors of heart failure progression. 2005 , 24, 2190-5	19
268	Acute haemodynamic effects of IL-6 treatment in vivo: involvement of vagus nerve in NO-mediated negative inotropism. 2005 , 30, 236-42	6
267	Depressive symptoms and inflammation among heart failure patients. 2005 , 150, 132-6	78
266	Neurohormonas y citocinas en la insuficiencia cardíaca. Correlación con la reserva de flujo coronario. 2005 , 58, 1273-1277	2
265	Neurohormones and Cytokines in Heart Failure. Correlation With Coronary Flow Reserve. 2005 , 58, 1273-1277	1
264	Dietary fat intake and proinflammatory cytokine levels in patients with heart failure. 2005 , 11, 613-8	44
263	Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. 2005 , 46, 2018-21	44
262	Cardiovascular Biomarkers. 2006 ,	2
261	Acute renal failure: much more than a kidney disease. 2006 , 26, 105-13	105
260	Biomarkers of Inflammation. 2006 , 295-318	
259	The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure. 2006 , 12, 122-7	55

- 258 Cardiostrophin-1 induces interleukin-6 synthesis in human umbilical vein endothelial cells. **2006**, 36, 101-6 27
- 257 Increased productivity of tumor necrosis factor-alpha in helper T cells in patients with systolic heart failure. **2006**, 111, 405-12 28
- 256 The role of intravenous immunoglobulin in the treatment of chronic heart failure. **2006**, 112, 40-5 26
- 255 In vitro endothelial cell activation and inflammatory responses in end-stage heart failure. **2006**, 101, 1466-73 7
- 254 Central neurotensin, alpha-melanocyte-stimulating hormone (alpha-MSH) is upregulated in patients with congestive heart failure. **2006**, 45, 429-34 12
- 253 Nutritional recommendations for patients with heart failure. **2006**, 21, 261-8 19
- 252 The anti-inflammatory properties of cocoa flavanols. **2006**, 47 Suppl 2, S163-71; discussion S172-6 87
- 251 Anti-inflammatory effect of cardiac resynchronization therapy. **2006**, 29, 753-8 34
- 250 Altered chemokine receptor profile on circulating leukocytes in human heart failure. **2006**, 44, 83-101 11
- 249 Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review. **2006**, 11, 333-4 22
- 248 Systemic inflammation in heart failure--the whys and wherefores. **2006**, 11, 83-92 208
- 247 Immune modulation therapy in heart failure. **2006**, 12, 91-6; quiz 97-8 4
- 246 Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE. **2006**, 8, 451-9 33
- 245 Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. **2006**, 291, H106-13 90
- 244 Plasma level of cardiostrophin-1 as a prognostic predictor in patients with chronic heart failure. **2007**, 9, 1032-7 33
- 243 Increased interleukin-6 receptor expression in the paraventricular nucleus of rats with heart failure. **2007**, 292, R1165-73 15
- 242 Acute heart failure associated with high admission blood pressure--a distinct vascular disorder?. **2007**, 9, 178-83 37
- 241 Role of bacterial endotoxin in chronic heart failure: the gut of the matter. **2007**, 28, 15-23 67

240	Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. 2007 , 71, 327-30	72
239	Increased levels of C-type natriuretic peptide in patients with idiopathic left ventricular dysfunction. 2007 , 28, 1068-73	29
238	Immune status evaluation of patients with chronic heart failure. 2007 , 37, 150-4	10
237	Cardiotrophin-1 induces interleukin-6 synthesis in human monocytes. 2007 , 38, 137-44	25
236	Atrial fibrillation is associated with increased neurohumoral activation and reduced exercise tolerance in patients with non-ischemic dilated cardiomyopathy. 2007 , 118, 206-14	28
235	A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design. 2007 , 23, 369-76	12
234	Potential mechanisms of benefit with thalidomide in chronic heart failure. 2007 , 7, 127-34	5
233	Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. 2007 , 61, 611-21	28
232	Role of inflammation in the progression of heart failure. 2007 , 9, 236-41	139
231	Expression of interferon-gamma and interleukin-4 production in CD4+ T cells in patients with chronic heart failure. 2007 , 22, 178-83	28
230	The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran Affairs patients receiving tumor necrosis factor alpha antagonists. 2007 , 27, 369-73	41
229	Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. 2007 , 102, 279-97	122
228	Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. 2007 , 102, 393-411	132
227	Adenoviral beta-adrenergic receptor kinase inhibitor gene transfer improves exercise capacity, cardiac contractility, and systemic inflammation in a model of pressure overload hypertrophy. 2008 , 22, 373-81	4
226	Effects of exercise training on inflammatory markers in patients with heart failure. 2008 , 13, 39-49	38
225	Digoxin and digoxin-like immunoreactive factors (DLIF) modulate the release of pro-inflammatory cytokines. 2008 , 57, 519-23	17
224	Imidaprilat inhibits matrix metalloproteinase-2 activity in human cardiac fibroblasts induced by interleukin-1beta via NO-dependent pathway. 2008 , 126, 414-20	16
223	Improved exercise capacity and reduced systemic inflammation after adenoviral-mediated SERCA-2a gene transfer. 2008 , 145, 257-65	8

222	Anti-inflammatory effects of Z23 on LPS-induced inflammatory responses in RAW264.7 macrophages. 2008 , 120, 447-51	31
221	Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. 2008 , 45, 261-9	60
220	Cytokines and myocardial dysfunction: state of the art. 2008 , 14, 61-74	74
219	Post-thyroidectomy thyroxine replacement dose in patients with or without compensated heart failure: the role of cytokines. 2008 , 41, 121-6	4
218	Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. 2008 , 371, 228-36	136
217	Nutritional considerations in heart failure. 2008 , 43, 117-32; vii	6
216	Tumor necrosis factor-alpha and mortality in heart failure: a community study. 2008 , 118, 625-31	116
215	Inflammation in chronic heart failure. 2008 , 42, 1002-16	30
214	Lower levels of the host protective IL-10 in DCM--a feature of autoimmune pathogenesis?. 2008 , 41, 478-83	10
213	gp130-mediated pathway and heart failure. 2008 , 4, 427-37	11
212	Beta-blockade does not alter plasma cytokine concentrations and ventricular function in young adults with right ventricular dysfunction secondary to operated congenital heart disease. 2008 , 72, 747-52	15
211	Morphological and molecular changes of the myocardium after left ventricular mechanical support. 2008 , 4, 157-69	27
210	Effective nocturnal oxygen therapy increases circulating level of tumor necrosis factor-alpha in heart failure. 2008 , 9, 64-7	
209	Myocarditis and dilated cardiomyopathy: possible connections and treatments. 2008 , 9, 666-71	5
208	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. 2009 , 11, 119-29	248
207	Cardiotrophin-1 induces tumor necrosis factor alpha synthesis in human peripheral blood mononuclear cells. 2009 , 2009, 489802	7
206	Smoking and atherosclerotic cardiovascular disease: part II: role of cigarette smoking in cardiovascular disease development. 2009 , 3, 617-53	29
205	Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling. 2009 , 2, 624-32	32

204	Circulating proinflammatory cytokines and N-terminal pro-brain natriuretic peptide significantly decrease with recovery of left ventricular function in patients with dilated cardiomyopathy. 2009 , 324, 139-45	11
203	Right ventricular beneficial effects of beta adrenergic receptor kinase inhibitor (betaARKct) gene transfer in a rat model of severe pressure overload. 2009 , 63, 331-6	7
202	The immune system and chronic heart failure: is the heart in control?. 2009 , 53, 1013-20	55
201	Pathophysiology of acute decompensated heart failure. 2009 , 5, 9-17, v	12
200	Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. 2009 , 3, 513-523	22
199	IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. 2009 , 296, H1694-704	86
198	Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. 2009 , 27, 418-24	39
197	The failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule?. 2010 , 8, 114-21	5
196	Decreased myocardial expression of dystrophin and titin mRNA and protein in dilated cardiomyopathy: possibly an adverse effect of TNF-alpha. 2010 , 30, 520-30	6
195	Altered expression of pro- and anti-inflammatory cytokines is associated with reduced cardiac function in rats following coronary microembolization. 2010 , 342, 183-90	19
194	Biomarkers of inflammation in heart failure. 2010 , 15, 331-41	153
193	TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. 2010 , 127, 295-314	303
192	Changes in the production of IL-10 and TNF-alpha in skeletal muscle of rats with heart failure secondary to acute myocardial infarction. 2010 , 94, 293-300, 313-20	9
191	The beneficial effect of n-3 polyunsaturated fatty acids on doxorubicin-induced chronic heart failure in rats. 2010 , 38, 940-8	28
190	Targeting the vicious inflammation-oxidative stress cycle for the management of heart failure. 2010 , 13, 1033-49	115
189	Defective circulating CD4CD25+Foxp3+CD127(low) regulatory T-cells in patients with chronic heart failure. 2010 , 25, 451-8	61
188	Separate mechanisms cause anemia in ischemic vs. nonischemic murine heart failure. 2010 , 298, R808-14	12
187	Molecular determinants of the cardiometabolic phenotype. 2010 , 10, 109-23	4

186	Circulating cytokine levels in mice with heart failure are etiology dependent. 2010 , 108, 1357-64	38
185	Early inflammatory response during the development of right ventricular heart failure in a rat model. 2010 , 12, 653-8	44
184	Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. 2011 , 161, 915.e1-9	84
183	Cytokine gene polymorphisms are associated with markers of disease severity and prognosis in patients with idiopathic dilated cardiomyopathy. 2011 , 54, 68-73	17
182	Systemic inflammation and cell activation reflects morbidity in chronic heart failure. 2011 , 56, 593-9	39
181	Antiinflammatory autoimmune cellular responses to cardiac troponin I in idiopathic dilated cardiomyopathy. 2011 , 17, 359-65	6
180	Levosimendan improves pro/anti-inflammatory cytokines imbalance in male patients with advanced heart failure. A randomized, double-blind, placebo-controlled study. 2011 , 147, 314-5	3
179	Functional and molecular effects of imidazoline receptor activation in heart failure. 2011 , 88, 493-503	12
178	Beta blocker metoprolol protects against contractile dysfunction in rats after coronary microembolization by regulating expression of myocardial inflammatory cytokines. 2011 , 88, 1009-15	15
177	Relationship between dietary folate intake and plasma monocyte chemoattractant protein-1 and interleukin-8 in heart failure patients. 2011 , 49, 62-6	8
176	Activation of Inflammatory Mediators in Heart Failure. 2011 , 163-184	1
175	HMGB1 as a predictor of infarct transmural and functional recovery in patients with myocardial infarction. 2011 , 270, 245-53	53
174	The promise of cardiovascular biomarkers in assessing children with cardiac disease and in predicting cardiovascular events in adults. 2011 , 32, 25-34	6
173	Acute myocardial ischemia directly modulates the expression of brain natriuretic peptide at the transcriptional and translational levels via inflammatory cytokines. 2011 , 670, 7-12	16
172	TNF α myocardial ischemia/reperfusion, remodeling and heart failure. 2011 , 16, 49-69	175
171	Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation. 2011 , 16, 137-45	47
170	Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN- γ patients with chronic heart failure. 2011 , 9, 28	51
169	Cystatin C, NT-proBNP, and inflammatory markers in acute heart failure: insights into the cardiorenal syndrome. 2011 , 16, 302-10	16

168	Increased inflammatory response in patients with dilated cardiomyopathy is associated with dyslipidemia: Effects of statin therapy. 2011 , 62, 55-61	0
167	Transforming growth factor- β governing the transition from inflammation to fibrosis in heart failure with preserved left ventricular function. 2011 , 4, 5-7	28
166	Blood gene expression signatures associate with heart failure outcomes. 2011 , 43, 392-7	18
165	Reduced cardiorespiratory fitness after stroke: biological consequences and exercise-induced adaptations. 2012 , 2012, 959120	76
164	New insights into HLA-G and inflammatory diseases. 2012 , 11, 448-63	31
163	Cardiac intercellular communication: are myocytes and fibroblasts fair-weather friends?. 2012 , 5, 768-82	40
162	The potential role of sphingolipid-mediated cell signaling in the interaction between hyperglycemia, acute myocardial infarction and heart failure. 2012 , 16, 791-800	20
161	Type D personality and course of health status over 18 months in outpatients with heart failure: multiple mediating inflammatory biomarkers. 2012 , 26, 301-10	20
160	Inflammatory cytokines in heart failure: mediators and markers. 2012 , 122, 23-35	220
159	Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. 2012 , 60, 1031-42	268
158	Transforming growth factor beta-1 and incidence of heart failure in older adults: the Cardiovascular Health Study. 2012 , 60, 341-5	12
157	Optimizing the parameters of vagus nerve stimulation by uniform design in rats with acute myocardial infarction. 2012 , 7, e42799	27
156	Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure. 2012 , 53, 182-6	22
155	Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. 2012 , 17, 177-90	127
154	TNF revisited: osteoprotegerin and TNF-related molecules in heart failure. 2012 , 9, 92-100	22
153	Cognitive/affective and somatic/affective symptom dimensions of depression are associated with current and future inflammation in heart failure patients. 2012 , 136, 567-76	44
152	Acute heart failure: patient characteristics and pathophysiology. 2013 , 10, 427-33	21
151	How can we cure a heart "in flame"? A translational view on inflammation in heart failure. 2013 , 108, 356	77

150	Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. 2013 , 38, 341-9	70
149	Is tumor necrosis factor- β friend or foe for chronic heart failure?. 2013 , 113, 492-4	22
148	The immunological axis in heart failure: importance of the leukocyte differential. 2013 , 18, 835-45	40
147	Low-level laser therapy improves the inflammatory profile of rats with heart failure. 2013 , 28, 1007-16	31
146	Heart failure after allogeneic hematopoietic stem cell transplantation. 2013 , 167, 2502-6	8
145	Serum β -carotene concentrations and the risk of congestive heart failure in men: a population-based study. 2013 , 168, 1841-6	41
144	Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). 2013 , 6, 91-8	37
143	Nutrition intervention to decrease symptoms in patients with advanced heart failure. 2013 , 36, 120-45	14
142	Myocardial cytokine expression in dogs with systemic and naturally occurring cardiac diseases. 2013 , 74, 408-16	10
141	The role of B-cells in heart failure. 2013 , 9, 15-9	21
140	New insights in research about acute ischemic myocardial injury and inflammation. 2013 , 12, 47-54	10
139	Tumor Necrosis Factor- β Triad: Psoriasis, Cardiovascular Disease, and Depression. 2013 , 19a, 41-49	2
138	The relationship between late gadolinium enhancement imaging and myocardial biopsy in the evaluation of chronic heart failure patients with suspected myocarditis. 2014 , 11, 404-8	
137	Remote ischemic conditioning improves coronary microcirculation in healthy subjects and patients with heart failure. 2014 , 8, 1175-81	38
136	Fibrosis markers and CRIM1 increase in chronic heart failure of increasing severity. 2014 , 19, 214-21	3
135	Activation of lymphocyte autophagy/apoptosis reflects haemodynamic inefficiency and functional aerobic impairment in patients with heart failure. 2014 , 127, 589-602	15
134	Markers of inflammation in recipients of continuous-flow left ventricular assist devices. 2014 , 60, 657-63	25
133	Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. 2014 , 11, 146-55	37

132	Circulating interleukin-6 levels are associated with abdominal aortic aneurysm presence: a meta-analysis and meta-regression of case-control studies. 2014 , 28, 1913-22	10
131	Heart-kidney crosstalk and role of humoral signaling in critical illness. 2014 , 18, 201	67
130	Interleukin 6(-174G/C) variant and its circulating levels in coronary artery disease patients and their first degree relatives. 2014 , 37, 314-21	19
129	Biomarkers for cardiac cachexia: reality or utopia. 2014 , 436, 323-8	12
128	IL-6 signalling in patients with acute ST-elevation myocardial infarction. 2014 , 4, 8-13	40
127	Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. 2014 , 19, 681-94	104
126	Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia. 2014 , 47, 8-15	31
125	The hemodynamic and nonhemodynamic crosstalk in cardiorenal syndrome type 1. 2014 , 4, 103-12	26
124	Neurohumoral improvement and torsional dynamics in patients with heart failure after treatment with levosimendan. 2015 , 7, 153-157	4
123	Changes in fractalkine in patients with ST-elevation myocardial infarction. 2015 , 26, 516-20	4
122	Inflammatory Biomarkers in Refractory Congestive Heart Failure Patients Treated with Peritoneal Dialysis. 2015 , 2015, 590851	6
121	Vitamin D deficiency contributes to the reduction and impaired function of naïve CD45RA+ regulatory T cell in chronic heart failure. 2015 , 2015, 547697	11
120	The Role of Cytokines in Clinical Heart Failure. 2015 , 191-203	
119	Left Ventricular T-Cell Recruitment Contributes to the Pathogenesis of Heart Failure. 2015 , 8, 776-87	140
118	Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment. 2015 , 154, 1-12	27
117	The tumor necrosis factor-β238G/A and IL-6 -572G/C gene polymorphisms and the risk of idiopathic dilated cardiomyopathy: a meta-analysis of 25 studies including 9493 cases and 13,971 controls. 2015 , 53, 307-18	6
116	Electrical storm due to myocarditis in post-infarct patient: When two diseases meet. 2015 , 57, e347-e353	1
115	Cardiac cachexia: hic et nunc: "hic et nunc" - here and now. 2015 , 201, e1-12	15

114	Pro-Apoptotic Effects of Plasma from Patients with Cardiorenal Syndrome on Human Tubular Cells. 2015 , 41, 474-84	17
113	Inflammatory cytokines as biomarkers in heart failure. 2015 , 443, 71-7	68
112	Ultrasound modulates skeletal muscle cytokine levels in rats with heart failure. 2015 , 41, 797-805	8
111	Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. 2015 , 89, 1401-38	337
110	Cytokines evolution: Role in various diseases. 2015 , 5, 176-182	3
109	Longitudinal assessment of inflammation in recipients of continuous-flow left ventricular assist devices. 2015 , 31, 348-56	26
108	Innate immunity and the failing heart: the cytokine hypothesis revisited. 2015 , 116, 1254-68	375
107	Predicting outcome in patients under extracorporeal membrane oxygenation due to cardiogenic shock through dynamic change of lymphocytes and interleukins. 2015 , 7, 36-44	6
106	Circulating chemerin levels elevated in dilated cardiomyopathy patients with overt heart failure. 2015 , 448, 27-32	20
105	Association between serum total antioxidant status and coronary microvascular function in idiopathic dilated cardiomyopathy. 2015 , 40, 487-94	2
104	Pathophysiology of Heart Failure and an Overview of Therapies. 2016 , 271-339	1
103	New therapy, new challenges: The effects of long-term continuous flow left ventricular assist device on inflammation. 2016 , 215, 424-30	20
102	Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction. 2016 , 5,	38
101	Cardiac cachexia: hic et nunc. 2016 , 7, 246-60	74
100	Risk stratification based on nutritional screening on admission: Three-year clinical outcomes in hospitalized patients with acute heart failure syndrome. 2016 , 68, 392-398	14
99	Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease. 2016 , 118, 1786-807	287
98	Vagus nerve modulation of inflammation: Cardiovascular implications. 2016 , 26, 1-11	21
97	Cytokine expression in peripheral blood mononuclear cells of dogs with mitral valve disease. 2016 , 211, 45-51	8

96	The relationship of pro-inflammatory markers to vascular endothelial function after acute stroke. 2017 , 127, 486-492	13
95	Molecular mechanism of sarcopenia and cachexia: recent research advances. 2017 , 469, 573-591	75
94	A Study of TNF Pathway Activation in Schizophrenia and Bipolar Disorder in Plasma and Brain Tissue. 2017 , 43, 881-890	32
93	Inflammatory biomarkers and effect of exercise on functional capacity in patients with heart failure: Insights from a randomized clinical trial. 2017 , 24, 808-817	20
92	Evaluation of longitudinal left ventricular function in patients with coronary artery ectasia and vitamin D deficiency by 2D speckle tracking echocardiography. 2017 , 34, 397-406	4
91	The impact of obesity on heart failure. 2017 , 32, 196-202	19
90	Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets. 2017 , 31, 593-608	52
89	Effect of the Natural Cytokine Complex on the Structure and Metabolism of Contractile Myocardium Normally and under Increased Hemodynamic Load. 2017 , 164, 136-139	7
88	Inflammation in Heart Failure: known knowns and unknown unknowns. 2017 , 18, 1225-1233	16
87	Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy. 2017 , 7, 3490	20
86	IL-1 β gene polymorphism and serum levels in a Tunisian population with acute heart failure. 2017 , 11, 1069-1076	4
85	Associations between Gene Polymorphisms and Dilated Cardiomyopathy in a Chinese Population. 2017 , 2017, 4191365	6
84	JNK and NF- κ B signaling pathways are involved in cytokine changes in patients with congenital heart disease prior to and after transcatheter closure. 2018 , 15, 1525-1531	3
83	The Importance of Pro-inflammatory Cytokines in Patients with Chronic Heart Failure and Chronic Kidney Disease and Type 2 Diabetes. 2017 , 8,	
82	The NF- κ B regulates the SHP-1 expression in monocytes in congestive heart failure. 2017 , 22, 757-771	3
81	Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure. 2018 , 39, 331-353	13
80	Cardiac (myo)fibroblasts modulate the migration of monocyte subsets. 2018 , 8, 5575	16
79	Time Course of Flow-Mediated Dilation and Vascular Endothelial Growth Factor following Acute Stroke. 2018 , 27, 957-962	6

78	Soluble glycoprotein 130 is inversely related to severity of coronary atherosclerosis. 2018 , 23, 527-532	10
77	New methodologies to accurately assess circulating active transforming growth factor- β levels: implications for evaluating heart failure and the impact of left ventricular assist devices. 2018 , 192, 15-29	14
76	The Inflammatory Response to Ventricular Assist Devices. 2018 , 9, 2651	22
75	Soluble IL-1 receptor 2 is associated with left ventricular remodelling in patients with ST-elevation myocardial infarction. 2018 , 268, 187-192	10
74	Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy. 2018 , 7,	17
73	Arrhythmogenic mechanisms of obstructive sleep apnea in heart failure patients. 2018 , 41,	9
72	The Fracture Callus Is Formed by Progenitors of Different Skeletal Origins in a Site-Specific Manner. 2019 , 3, e10193	3
71	Exercise in Heart Failure-What Is the Optimal Dose to Improve Pathophysiology and Exercise Capacity?. 2019 , 16, 98-107	10
70	The pleiotropic association between IL-10 levels and CVD prognosis: Evidence from a meta-analysis. 2019 , 119, 37-46	5
69	Plasma levels of pro-inflammatory molecules and their expressions are associated with severity of heart failure: An investigation in Chinese cohort. 2019 , 17, 205873921983657	0
68	Heart-Kidney Cross-Talk. 2019 , 664-670.e3	1
67	Genetic determinants of responsiveness to mesenchymal stem cell injections in non-ischemic dilated cardiomyopathy. 2019 , 48, 377-385	15
66	HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer. 2020 , 39, 1335-1346	17
65	Galectin-3 is associated with severe heart failure and death: A hospital-based study in Chinese patients. 2020 , 91, e12826	4
64	Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure. 2020 , 25, 685-701	6
63	Chemokines profile in patients with chronic heart failure treated with cardiac resynchronization therapy. 2020 , 65, 102-110	0
62	The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases. 2020 , 12, 947-968	16
61	Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol. 2020 , 2020, 7262474	5

60	Changes of inflammatory and oxidative stress biomarkers in dogs with different stages of heart failure. 2020 , 16, 433	2
59	Biphasic changes in TGF- β signaling drive NSAID-induced multi-organ damage. 2020 , 160, 125-140	4
58	Nanotechnology Solutions for Controlled Cytokine Delivery: An Applied Perspective. 2020 , 10, 7098	4
57	Cardiac Cachexia: A Well-Known but Challenging Complication of Heart Failure. 2020 , 15, 2041-2051	8
56	Cardiac Fibrosis Is Associated With Decreased Circulating Levels of Full-Length CILP in Heart Failure. 2020 , 5, 432-443	8
55	Associations between gene polymorphisms and dilated cardiomyopathy in a Chinese population. 2020 , 14, 441-450	1
54	Cytokine Profile in Striated Muscle Laminopathies: New Promising Biomarkers for Disease Prediction. 2020 , 9,	2
53	Diaphragm weakness and proteomics (global and redox) modifications in heart failure with reduced ejection fraction in rats. 2020 , 139, 238-249	3
52	Macrophage Activities in Myocardial Infarction and Heart Failure. 2020 , 2020, 4375127	13
51	Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide. 2021 , 26, 237-253	13
50	Mortal Interaction Between Hemophagocytic Syndrome and Newly Developed Heart Failure. 2021 , 116, 395-401	1
49	Functional and molecular effects of TNF- β on human iPSC-derived cardiomyocytes. 2021 , 52, 102218	3
48	Heart failure risk estimation based on novel biomarkers. 2021 , 21, 655-672	1
47	In-depth review of cardiopulmonary support in COVID-19 patients with heart failure. 2021 , 13, 299-309	
46	CMV Infection Is Directly Related to the Inflammatory Status in Chronic Heart Failure Patients. 2021 , 12, 687582	2
45	In-depth review of cardiopulmonary support in COVID-19 patients with heart failure. 2021 , 13, 298-308	2
44	Organ-on-a-chip platforms for evaluation of environmental nanoparticle toxicity. 2021 , 6, 2801-2819	15
43	Management of inflammation in cardiovascular diseases. 2021 , 173, 105912	1

42	Vagal Nerve Stimulation for the Treatment of Heart Failure. 2017 , 157-179	1
41	Pathophysiology of Acute Decompensated Heart Failure. 2017 , 81-88	1
40	More than destructive: neutrophil-derived serine proteases in cytokine bioactivity control. 2001 , 69, 197-206	28
39	Lack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overload. 2011 , 6, e18668	21
38	The circulating level of interleukins 6 and 18 in ischemic and idiopathic dilated cardiomyopathy. 2019 , 11, 132-137	4
37	Possible mechanisms of cardiac contractile dysfunction and electrical changes in ammonium chloride induced chronic metabolic acidosis in Wistar rats. 2016 , 65, 927-940	5
36	Ameliorated stress related proteins are associated with improved cardiac function by sarcoplasmic reticulum calcium ATPase gene transfer in heart failure. 2012 , 9, 269-77	2
35	Polymorphisms of tumor necrosis factor-alpha and interleukin-6 gene and C-reactive protein profiles in patients with idiopathic dilated cardiomyopathy. 2014 , 34, 407-14	9
34	The renewed concept of the Batista operation for ischemic cardiomyopathy: maximum ventricular reduction. 2011 , 26, 544-51	2
33	Neurofilament light: a possible prognostic biomarker for treatment of vascular contributions to cognitive impairment and dementia. 2021 , 18, 236	1
32	Neurohormones in Advanced Heart Failure. 2000 , 3-23	
31	The Role of Interleukin-6 in the Failing Heart. 2001 , 27-34	0
30	Role of chemokines in the pathogenesis of congestive heart failure. 2003 , 351-367	
29	The clinical experience with anti-cytokine therapy in heart failure. 2003 , 95-110	
28	The Interleukin-6 Family of Cytokines and their Receptors in Patients with Congestive Heart Failure. 2003 , 39-46	
27	Dilated Cardiomyopathies and Congestive Heart Failure. 2003 , 35-65	
26	The role of IL-6 in experimental and clinical heart failure. 2003 , 143-151	1
25	????????(????2003????). 2004 , 12, 106-111	

24	Cardiovascular Diseases. 2006 , 1101-1109	
23	Myocardial Proteases and Matrix Remodeling in Acute Myocarditis and Inflammatory Cardiomyopathy. 2010 , 71-88	
22	Pathophysiology of Acute Decompensated Heart Failure. 2012 , 77-83	1
21	Cardiac Autonomic Control in Relation to Other Prognostic Markers in Idiopathic Dilated Cardiomyopathy. 2015 , 05, 107-119	
20	Cardiovascular Diseases. 975-982	
19	Heart Failure with Normal Left Ventricular Ejection Fraction (HFNEF). 2017 , 273-339	
18	Cardiorenal Syndrome and Heart Failure. 2017 , 227-238	
17	Cardiorenal Syndrome (CRS). 2017 , 371-401	
16	End-Organ Physiology Under Continuous-Flow Mechanical Circulatory Support. 2020 , 279-300	
15	ASSOCIATION OF CLINICAL COURSE OF HEART FAILURE WITH INTERLEUKIN LEVELS IN PATIENTS WITH NONTOXIC GOITER. 2020 , 1, 187	
14	Immunomodulatory effects of cardiotrophin-1 on in vitro cytokine production of monocytes & CD4 + T-lymphocytes. 2012 , 136, 471-6	1
13	The G-308A polymorphism of the TNF-alpha gene does not predict changes in cardiac function in response to medical therapy for idiopathic dilated cardiomyopathy. 2008 , 19, 254-8	3
12	Salt intake is associated with inflammation in chronic heart failure. 2014 , 8, 89-93	9
11	Synergistic effect of estradiol and testosterone protects against IL-6-induced cardiomyocyte apoptosis mediated by TGF- β . 2018 , 11, 10-26	0
10	Autocrine S100B in astrocytes promotes VEGF-dependent inflammation and oxidative stress and causes impaired neuroprotection. 2021 , 1	0
9	COVID-lateral damage: cardiovascular manifestations of SARS-CoV-2 infection. 2021 ,	0
8	Cognitive Impairment in Heart Failure-A Review.. 2022 , 11,	0
7	Cardiac Cachexia: Unaddressed Aspect in Cancer Patients.. 2022 , 11,	1

- 6 Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.. **2021**, 18, 908-951 2
- 5 Role of Cardiomyocyte-Derived Exosomal MicroRNA-146a-5p in Macrophage Polarization and Activation.. **2022**, 2022, 2948578 0
- 4 Pathophysiology of heart failure and an overview of therapies. **2022**, 149-221
- 3 Expression of interleukin 1, interleukin 27, and TNF α genes in patients with ischemic cardiomyopathy versus idiopathic dilated cardiomyopathy: A case-control study. **2022**, 5, 0
- 2 Genetic Association between Polymorphisms of Interleukin-32 and Dilated Cardiomyopathy in Chinese Han Population. **2022**, 2022, 1-9 0
- 1 Erythrocyte Indices in Patients With Takotsubo Syndrome. **2023**, 22, 31-39 0